secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001171843-25-001049
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus appoints Roivant-affiliated CEO and new board after all prior directors resign
--------------------------------------------------------------------------------

- All seven directors resigned Feb 24; board reduced to five with new appointees including Roivant affiliates.
- Lindsay Androski named President and CEO, replacing interim CEO McElhaugh; she also serves as board chair.
- Androski receives $515k salary, 45% target bonus, and ~$750k option grant; three new directors are from Roivant.
- Company will pause investor meetings to review strategic options for hepatitis B pipeline and development plans.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/0001171843-25-001049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184325001049/f8k_022525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-001049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer